We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.
CEO – Biotech
Private equity: an opportunity biopharma should seize
European entry – How Biotechs Can Succeed in Europe
The Novasecta European MidPharma Report 2019
Getting Personal: Pharma’s Future Commercial Model
The Novasecta Global 100
Medical Affairs: Influencers of the Future
Spend Like an Investor
Launch excellence: Beyond the Six-Month Mantra
In Conversation with Cloud Pharmaceuticals’ Don Van Dyke
How to Get More from Mature Brands
What Pharma Should Do About Artificial Intelligence (AI)
The Novasecta European MidPharma Report 2018
How Ownership Influences Pharma Strategies
Grow through Strategic Collaborations
The Novasecta European MidPharma Report 2017
Digital Marketing is no Substitute for Sound Strategic Marketing
Breakthrough Innovation: Lessons for Pharma R&D
Pharma M&A is Too Expensive: Now What?
What Pharma Can Do About Brexit
How to Navigate the Digital Revolution in Pharma
Defragmenting R&D: Lessons from the Pioneers
Brand Reviews that Make a Difference
Practical Patient Centricity
Partner with your Legal Team for Successful R&D Collaborations
The Novasecta European MidPharma Report 2016
Beat the Trend: New Commercial Habits Required
Integrated and Open Innovation: The Best of Both Worlds
Better Partnerships: The Alternative to M&A?
Manage R&D to Create Value
Commercial and R&D: Value Lost in Translation?
The Novasecta European MidPharma Report 2015
Business growth: Bespoke strategists lead the way
Funding clinical development: More creativity required?
A Biotech-like Mentality in MidPharmas: The Winning Combination?